Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind Rogaine—is well coiffed to tap into the increasingly lush opportunity for hair r | ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.

Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm has lined up a listing.

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

This could be the biggest week for biotech IPOs in years — even if the government remains shuttered temporarily. Government funding lapsed this past Saturday, sparking a partial government shutdown ...